Vircell Highlights Diagnostic Innovations in Infectious Diseases at MEDICA 2025
Posted on 19 Nov 2025
Vircell is presenting a comprehensive suite of infectious disease diagnostic solutions crafted to meet the evolving demands of clinical laboratories at MEDICA 2025. The company is highlighting a broad portfolio encompassing immunological and molecular diagnostic solutions, along with its focus on global regulatory readiness.
At its booth in Hall 3-A30, Vircell is placing special focus on the VirClia series, its fully automated, random-access, continuous-loading CLIA analyzer platform. The lineup includes the VirClia Monotest format, which provides ready-to-use, self-contained assays with all required reagents in a single strip, including calibrators and controls. With an easy-to-run automated protocol and rapid turnaround, the VirClia Monotest system provides laboratories with high flexibility and seamless workflow integration.
A key highlight of the portfolio is the VirClia Lotus analyzer, designed for continuous-loading, random-access serology processing and capable of adapting to varying laboratory volumes. The system delivers excellent turnaround times, with first results available in 70 minutes and subsequent results delivered every 35 seconds. The Lotus platform offers a panel of more than 90 infectious-disease parameters and accommodates up to 79 different monotests on board, along with 50 primary sample tubes.
On the molecular side, Vircell is showcasing its AmpliRun and AmpliRun Total ready-to-use control sets, developed to support validation and ongoing performance monitoring across a wide range of real-time PCR assays for viral, bacterial, fungal, and parasitic targets. AmpliRun DNA/RNA controls serve as independent third-party standards compatible with any molecular testing platform. Each control contains an inactivated and purified complete microbial genome, allowing amplification of any sequence.
AmpliRun Total Molecular Controls provide independent full-process controls for infectious-disease testing. They consist of whole inactivated pathogens suspended in a matrix that mimics human specimens. Containing the entire genome, they are compatible with any analysis platform and support comprehensive assay evaluation.
Complementing these controls, Vircell offers an extensive panel of real-time PCR kits for specific pathogens, together with a broad immunoassay portfolio that includes rapid tests, ELISA, and IFA formats. This comprehensive offering enables Vircell to support both smaller clinical laboratories and large, high-throughput reference centers.
Related Links:
Vircell
